Edition:
India

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,587JPY
11:30am IST
Change (% chg)

¥-53 (-1.14%)
Prev Close
¥4,640
Open
¥4,640
Day's High
¥4,645
Day's Low
¥4,561
Volume
3,377,300
Avg. Vol
5,271,558
52-wk High
¥6,693
52-wk Low
¥4,203

Select another date:

Tue, Jul 31 2018

UPDATE 2-Takeda operating profit halves, looks to asset sales to shore up finances

* Shire-related costs helped push debt ratio higher (Adds details from news conference)

Takeda Q1 profit tumbles 49 pct after asset sales, hit by generic drug competition

TOKYO, July 31 Japan's Takeda Pharmaceutical Co Ltd on Tuesday reported a 49 percent fall in first-quarter operating profit, affected by asset sales booked in the same quarter a year earlier and by generic drug competition for blood cancer treatment Velcade in the U.S.

Japan's Takeda gains U.S. approval for $62 billion Shire buy

TOKYO Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker.

UPDATE 2-Japan's Takeda gains US approval for $62 bln Shire buy

* Also needs approval from Takeda, Shire shareholders (Adds share movement)

Takeda gets key U.S. regulatory approval to buy Shire

TOKYO, July 10 Japan's Takeda Pharmaceutical Co Ltd said on Tuesday it received a key U.S. regulatory approval for its $62 billion deal to buy London-listed Shire Plc .

Japan's Takeda to sell Osaka headquarters, could raise 60 billion yen: Nikkei

TOKYO Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc , the Nikkei business daily reported on Thursday.

Japan's Takeda to sell Osaka headquarters, could raise Y60 bln - Nikkei

TOKYO, July 5 Japan's Takeda Pharmaceutical Co Ltd is selling its Osaka headquarters amid concerns over its finances due to its $62 billion deal to buy London-listed Shire Plc, the Nikkei business daily reported on Thursday.

Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor

TOKYO A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion acquisition of London-listed Shire Plc , failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday.

UPDATE 2-Takeda shareholders bin proposal from anti-Shire group; only 10 pct in favour

* Result casts doubt on its ability to gather necessary support

Takeda shareholder group proposal fails to pass at AGM

TOKYO, June 28 A group of Takeda Pharmaceutical Co Ltd shareholders trying to build support to block the $62 billion acquisition of London-listed Shire Plc failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday.

Select another date: